Comparison of three different combination therapies in the treatment of human brucellosis

Basit Öğe Kaydı
dc.authoridErsoy, Yasemin/0000-0001-5730-6682
dc.authorwosidErsoy, Yasemin/AAE-4811-2020
dc.contributor.authorErsoy, Y
dc.contributor.authorSonmez, E
dc.contributor.authorTevfik, MR
dc.contributor.authorBut, AD
dc.date.accessioned2024-08-04T20:15:12Z
dc.date.available2024-08-04T20:15:12Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- APR 01-04, 2001 -- ISTANBUL, TURKEYen_US
dc.description.abstractThe efficacy and tolerability of three different combination treatment regimens in human brucellosis were compared in 118 uncomplicated patients enrolled in a prospective study between May 1997 and December 2002. Brucellosis was diagnosed using standard clinical and microbiological findings. Patients with central nervous system involvement, spondylitis, endocarditis or children under 16 years of age were excluded from the study. Patients were randomly assigned to receive 400 mg of ofloxacin plus 600 mg of rifampicin (OR, n = 41),200 mg of doxycycline plus 600 mg of rifampicin (DR, n = 45) or 1 g intramuscularly streptomycin (administered for three weeks) plus 200 mg doxycycline (DS, n = 32) daily for 6 weeks. All patients were followed up at least 6 months after cessation of therapy. There was no statistical difference between the groups on relapse rates and clinical response to the treatment (P> 0.05). Five patients in OR (12.8%), six patients in DR (14.3%) and three patients in DS groups (9.7%) suffered relapse. The side-effects were seen in eight (19.5%), 21 (46.7%) and eight (25.0%) patients of OR, DR and DS groups, respectively. The use of combination therapy of ofloxacin plus rifampicin for 6 weeks was found to be as effective as DR and DS. The side-effects of therapy in OR and DS groups was less severe than in the DR group.en_US
dc.description.sponsorshipEuropean Soc Clin Microbiol & Infect Dis, European Study Grp Antimicrobial Policiesen_US
dc.identifier.doi10.1258/004947505774938765
dc.identifier.endpage212en_US
dc.identifier.issn0049-4755
dc.identifier.issue4en_US
dc.identifier.pmid16354469en_US
dc.identifier.scopus2-s2.0-30844431530en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage210en_US
dc.identifier.urihttps://doi.org/10.1258/004947505774938765
dc.identifier.urihttps://hdl.handle.net/11616/94227
dc.identifier.volume35en_US
dc.identifier.wosWOS:000234215000007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherRoyal Soc Medicine Press Ltden_US
dc.relation.ispartofTropical Doctoren_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMelitensisen_US
dc.subjectCiprofloxacinen_US
dc.subjectDoxycyclineen_US
dc.subjectRifampicinen_US
dc.subjectQuinolonesen_US
dc.subjectOfloxacinen_US
dc.subjectEfficacyen_US
dc.titleComparison of three different combination therapies in the treatment of human brucellosisen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu